Zai Lab (ZLAB) to Release Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Zai Lab to post earnings of ($0.65) per share and revenue of $110.15 million for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Zai Lab Price Performance

Shares of NASDAQ:ZLAB opened at $33.91 on Wednesday. The company has a market cap of $3.71 billion, a P/E ratio of -12.24 and a beta of 1.02. Zai Lab has a 1 year low of $13.48 and a 1 year high of $36.60. The stock’s fifty day moving average price is $27.17 and its 200-day moving average price is $25.57.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald upgraded Zai Lab to a “strong-buy” rating in a research report on Wednesday, February 5th.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $26.28, for a total value of $199,281.24. Following the completion of the sale, the insider now directly owns 33,834 shares of the company’s stock, valued at $889,157.52. This trade represents a 18.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 13.88% of the stock is currently owned by company insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.